A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: Result from CALGB study 9211

Leukemia

Volumn 17, Issue 2, 2003, Pages 323-327

  Byrd, J C ^a   Peterson, B ^b   Piro, L ^c   Saven, A ^c   Vardiman, J W ^d   Larson, R A ^d   Schiffer, C ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Chronic lymphocytic leukemia; Cladribine; Resistance

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTILEUKEMIC AGENT; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; DOXORUBICIN; FLUDARABINE; OBLIMERSEN; PENTOSTATIN; PREDNISONE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LEUKEMIA; BACTERIAL INFECTION; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INFUSION; DRUG RESPONSE; DYSPNEA; ESOPHAGITIS; FATIGUE; FEMALE; GRANULOCYTOPENIA; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; LYMPHADENOPATHY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; THROMBOCYTOPENIA; TOXOPLASMOSIS;

EID: 0037325637     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402752     Document Type: Article

References (40)

1. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
2. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981 ; 48: 198-216.
3. Grever MR, Kopecky KJ, Coltman CA et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457-459.
4. Keating MJ, Kantarjian H, Talpaz M et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
5. Piro LD, Carrera CJ, Beutler E et al. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069-1073.
6. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11: 679-689.
7. Tallman MS, Hakimian D, Zanzig C et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 983-988.
8. Delannoy A, Ferrant A, Martiat P et al. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia. Nouv Rev Fr Hematol 1994; 36: 311-315.
9. Ho AD, Thaler J, Stryckmans P et al. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 1990; 82: 1416-1420.
10. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol 1989; 7: 433-438.
11. Grever MR, Leiby JM, Kraut EH et al. Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985; 3: 1196-1201.
12. Keating MJ, Kantarjian H, O'Brien S et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44-49.
13. The French Cooperative Group on CLL, Johnson S, Smith AG et al. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 1996; 347: 1432-1438.
14. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-1757.
15. Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319-2325.
16. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056-1061.
17. Saven A, Lemon RH, Piro LD. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328: 812-813.
18. Delannoy A, Hanique G, Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328: 812.
19. O'Brien S, Kantarjian H, Estey E et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330: 319-322.
20. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
21. Genini D, Adachi S, Chao Q et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria Blood 2000; 96: 3537-3543.
22. Byrd JC, McGrail LH, Hospenthal DR et al. Herpes virus infections occur frequently following treatment with fludarabine: Results of a prospective natural history study Br J Haematol 1999; 105: 445-447.
23. Perkins JG, Flynn JM, Byrd JC. Frequency and type of infections in fludarabine refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2001 (in press).
24. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-2448.
25. Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567-1574.
26. Keating MJ, Byrd JC, Rai KR et al. Multicenter study of campath-1H in patients with chronic lymphocytic leukemia refractory to fludarabine. Blood 1999; 94: 705a (Abstr. 3117).
27. O'Brien S, Thomas DA, Kantarjian H et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-2170.
28. Byrd JC, Murphy T, Howard R et al. Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma: a feasible and active regimen. J Clin Oncol 2001; 19: 2153-2164.
29. Chandra J, Niemer I, Gilbreath J et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998; 92: 4220-4228.
30. Byrd JC, Shinn C, Ravi R et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999; 94: 1401-1418.
31. Byrd JC, Waselenko JK, Keating M et al. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol 2000; 27: 587-597.
32. El Rouby S, Thomas A, Costin D et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452-3459.
33. Cordone I, Masi S, Mauro FR et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker for disease progression and poor prognosis. Blood 1998; 91: 4132-4349.
34. Dohner H, Stilgenbauer S, James MR et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89: 2516-2522.
35. Dohner H, Fischer K, Bentz M et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
36. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Eng J Med 2000; 343: 1910-1916.
37. Hamblin TJ, Davis Z, Gardiner A et al. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
38. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
39. Ibrahim S, Keating M, Do KA et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181-186.
40. Kitada S, Ajar S, Andersen J et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389.